Dipna Pharmachem Approves Secretarial Auditor FY 2025-26
Dipna Pharmachem Limited has successfully concluded its postal ballot process for the appointment of M/s. Jay Pandya & Associates as Secretarial Auditor for the financial year 2025-26. The resolution received strong shareholder approval, with 99.77% of valid votes cast in favour. The e-voting process was conducted from April 23, 2026, to May 22, 2026, in compliance with SEBI regulations.

*this image is generated using AI for illustrative purposes only.
Dipna Pharmachem Limited has announced the outcome of its postal ballot process for the appointment of a secretarial auditor for the financial year 2025-26. The company sought shareholder approval for the appointment of M/s. Jay Pandya & Associates, Company Secretaries, Ahmedabad, through an ordinary resolution. The remote e-voting period concluded on May 22, 2026.
The resolution was approved with the requisite majority by the shareholders. The scrutinizer's report confirmed the outcome, detailing the votes cast in favour and against the proposal. The appointment is effective for the specified financial year.
Voting Results
The postal ballot results indicate strong shareholder support for the resolution. A total of 2,652,450 valid votes were cast, with the majority favouring the appointment.
| Resolution No. | Votes in favour | % of Valid Votes | Votes against | % of Valid Votes | Invalid Votes |
|---|---|---|---|---|---|
| 01 | 2,646,450 | 99.77 | 6,000 | 0.23 | 0 |
Process Details
The remote e-voting process was conducted in compliance with the provisions of Section 108 and 110 of the Companies Act, 2013, and relevant SEBI regulations. The e-voting period was open from April 23, 2026, to May 22, 2026. The cut-off date for determining shareholder eligibility was April 17, 2026. M/s. Jay Pandya & Associates acted as the scrutinizer for the process.
Historical Stock Returns for Dipna Pharmachem
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | -6.80% | -11.96% | -58.32% | -68.57% | -74.53% |
How might M/s. Jay Pandya & Associates' secretarial audit findings for FY 2025-26 impact Dipna Pharmachem's corporate governance ratings and investor confidence?
What potential compliance gaps or regulatory risks could the new secretarial auditor uncover given the pharmaceutical sector's evolving regulatory landscape?
Will the 0.23% dissenting shareholder votes signal any underlying concerns about Dipna Pharmachem's governance practices that could influence future resolutions?
































